EAY191 / ComboMATCH — Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Phase 2 · Solid Tumors

Population

Patients with locally advanced or advanced solid tumors bearing targetable genomic alterations.

Primary Endpoint

Enrollment onto matched treatment substudies (with substudy-specific efficacy endpoints)

Rationale

Single-agent targeted therapy responses in NCI-MATCH were often short-lived due to resistance; rational combinations may overcome resistance and improve outcomes.

What It Could Change

Positive substudies would establish genomically matched drug combinations as effective options for molecularly defined tumor subsets.